Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

Cost-effectiveness of immunization strategies to protect infants against respiratory syncytial virus in the Netherlands

The European Medicines Agency has authorized two interventions to prevent lower respiratory tract disease due to respiratory syncytial virus (RSV-LRTD) in infants: nirsevimab, a monoclonal antibody, and bivalent stabilized prefusion F subunit maternal vaccine (RSVpreF). In the Netherlands, RSV-LRTD...

Full description

Saved in:
Bibliographic Details
Main Authors: Annefleur C. Langedijk, Floris van den Dungen, Lisette Harteveld, Jennie van den Boer, Lucy Smit, Ahuva Averin, Erin Quinn, Mark Atwood, Amy Law, Diana Mendes, Marlies van Houten
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Respiratory syncytial virus
the Netherlands
maternally acquired immunity
passive immunization
monoclonal antibody
cost-effectiveness analysis
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2521912
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2025.2521912

Similar Items